Articles

Multicenter prospective phase II study of decitabine priming with low-dose idarubicin, cytarabine, and G-CSF in children with refractory or relapsed acute myeloid leukemia

Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou
Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China; Pediatric Hematol and Oncol Key Laboratory of Higher Education Institutions in Jiangsu Province, Suzhou
Department of Hematology and Oncology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou
Department of Pediatrics, The Second Affiliated Hospital ofAnhui Medical University, Anhui Medical University, Hefei
Department of Pediatrics, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei
Department of Hematology and Oncology, Children's Hospital of Fudan University, Fudan University, Shanghai
Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China; Pediatric Hematol and Oncol Key Laboratory of Higher Education Institutions in Jiangsu Province, Suzhou
Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning
Department of Pediatrics, Qilu Hospital of Shandong University, Shandong University, Qingdao
Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou
Department of Hematology and Oncology, Kaifeng Children's Hospital, Kaifeng
Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, Guangxi Medical University, Nanning
Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou
Department of Hematology and Oncology, Kaifeng Children's Hospital, Kaifeng
Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou
Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou
Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou
Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou
Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN
Department of Hematology and Oncology, Children's Hospital of Fudan University, Fudan University, Shanghai
Department of Pediatrics, Qilu Hospital of Shandong University, Shandong University, Qingdao
Department of Pediatrics, The Second Affiliated Hospital ofAnhui Medical University, Anhui Medical University, Hefei
Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou
Department of Hematology and Oncology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou
Division of Leukemia/Lymphoma, Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN
Department of Hematology and Oncology, Children's Hospital of Soochow University, Soochow University, Suzhou, China; Pediatric Hematol and Oncol Key Laboratory of Higher Education Institutions in Jiangsu Province, Suzhou, China; Pediatric Hematol and Oncol Center of Jiangsu Province, Suzhou
Haematologica Early view Feb 5, 2026 https://doi.org/10.3324/haematol.2025.289170